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BACKGROUND: Immunostaining for cytokeratin 7 (CK7) and
cytokeratin 20 (CK20) has a characteristic pattern in Barrett’s esoph-
agus (BE), but reports regarding its sensitivity and specificity are
inconsistent. Intestinal metaplasia of the gastric cardia (CIM) is his-
tologically similar to BE, but with no abnormal endoscopic findings. 
OBJECTIVES: To evaluate the sensitivity and specificity of a semi-
quantitative CK7/CK20 immunostaining pattern for the diagnosis of
BE, and to further elucidate the pathogenesis of CIM. 
METHODS: Tissues were examined by hematoxylin and eosin and
periodic acid schiff/alcian blue stains, and then were immunostained
with CK7 and CK20 antibodies. Correlations with other clinical
parameters were statistically analyzed. 
RESULTS: When values were revised based on follow-up data and
auxiliary testing, all BE cases (100%) displayed the characteristic BE
CK7/CK20 immunostaining pattern, compared with 66% of CIM
cases. In the subgroup of patients who were endoscopically and
immunohistochemistry-positive but histologically negative, all
patients except for one had documented BE when clinical history,
auxiliary testing and follow-up were evaluated. There were no statis-
tically significant differences between BE and CIM regarding
Helicobacter pylori infection or the type of metaplasia (complete ver-
sus incomplete). The sensitivity of the CK7/CK20 pattern reached
100% in the subgroup of CIM patients with a history of acid reflux.
Of 26 cases of CIM where follow-up was available, four cases (15%)
progressed to BE, and one developed dysplasia. All four cases showed
the BE pattern of CK7/CK20 staining and were negative for H pylori
infection.
CONCLUSIONS: A semiquantitative CK7/CK20 pattern can be
used to confirm BE even in the absence of histological evidence. The
subgroup of CIM with acid reflux may develop into BE and may need
closer follow-up. 
Key Words: Barrett’s esophagus; Cardiac intestinal metaplasia;
CK7; CK20; Dysplasia; H pylori
L’œsophage de Barrett et la métaplasie 
intestinale du cardia : Deux problèmes faisant
partie du même spectre
HISTORIQUE : L’immunomarquage à la cytokératine 7 (CK7) et à la
cytokératine 20 (CK20) a un motif caractéristique dans l’œsophage de
Barrett (OB), mais les rapports au sujet de sa sensibilité et de sa spécificité
sont erratiques. La métaplasie intestinale du cardia gastrique (MIC) est
similaire à l’OB du point de vue histologique, mais elle ne s’accompagne
pas d’observations endoscopiques anormales.
OBJECTIFS : Évaluer la sensibilité et la spécificité d’un motif d’im-
munomarquage à CK7/CK20 semi-quantitatif pour diagnostiquer l’OB et
mieux déterminer la pathogenèse de la MIC.
MÉTHODOLOGIE : On a examiné les tissus par hématoxyline et
éosine et par réaction à l’acide périodique Schiff /Bleu Alcian, puis on les
a immunomarqués par des anticorps à la CK7 et la CK20. Les corrélations
avec d’autres paramètres cliniques ont fait l’objet d’analyses statistiques.
RÉSULTATS : Lorsqu’on a examiné les valeurs d’après des données de
suivi et des tests auxiliaires, tous les cas d’OB (100 %) ont affiché le motif
d’immunomarquage à CK7/CK20 caractéristique de l’OB, par rapport à
66 % des cas de MIC. Dans le sous-groupe de patients qui étaient positifs
d’après l’endoscopie et l’immunohistochimie mais négatifs d’après l’his-
tologie, tous les patients, sauf un, présentaient un OB documenté après
l’évaluation des antécédents cliniques, des tests auxiliaires et du suivi. On
ne remarquait aucune différence statistiquement significative entre l’OB
et la MIC pour ce qui est de l’infection par Helicobacter pylori ou du type
de métaplasie (complète ou incomplète). La sensibilité du motif à
CK7/CK20 atteignait 100 % dans le sous-groupe de patients atteints
d’une MIC ayant des antécédents de reflux acide. Des 26 cas de MIC pour
lesquels on possédait des données de suivi, quatre cas (15 %) se sont
détériorés en OB, et un, en dysplasie. Les quatre cas présentaient le motif
de coloration à CK7/CK20 et étaient négatifs à l’infection par H pylori.
CONCLUSIONS : Un motif à CK7/CK20 semi-quantitatif peut permet-
tre de confirmer un OB, même en l’absence de données histologiques. Le
sous-groupe de MIC avec reflux acide peut se détériorer en OB et exiger
un suivi plus étroit.
Barrett’s esophagus (BE) is an acquired condition in whichthe squamous epithelium at the distal esophagus is replaced
by intestinal epithelium with goblet cells (1). This metaplastic
process commonly develops from mucosal injuries as a result of
gastroesophageal reflux disease (2). BE is a major risk factor for
the development of esophageal adenocarcinoma (3), because
approximately 0.5% of patients with BE develop this malig-
nancy each year (4).
The normal histology of the squamocolumnar junction
(SCJ) and, in particular, the nature of the cardiac mucosa and
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whether it represents a normal anatomical segment or an
acquired condition, remains in dispute (5). Both cardiac intes-
tinal metaplasia (CIM) and BE are histologically identical,
characterized by the presence of intestinal metaplasia (IM)
with goblet cells. The two conditions are differentiated only by
the finding of endoscopically visible tongues of columnar
mucosa of any length, which would qualify the lesion as BE,
while endoscopically negative individuals are diagnosed with
CIM (5,6). Only a small proportion of patients with BE pres-
ent with endoscopically obvious long segments of columnar
epithelium (longer than 3 cm) above the gastroesophageal
junction (GEJ) (7,8). Short segment BE (shorter than 3 cm in
length), and more recently, ultrashort segment BE are more
difficult to recognize by endoscopy, potentially being confused
with CIM (9). Several attempts have been made to differenti-
ate reliably between these conditions based on their etiology
and the type of mucin produced (10,11), but the results were
not consistent. 
The significance of CIM is not well understood. Some
suggest that it is linked to Helicobacter pylori infection
(12,13), while others associate it with acid reflux (5,14,15).
Another study suggests that patients with short segment BE
have a higher risk for developing dysplasia than patients with
CIM (16). 
Cytokeratin 7 (CK7) and cytokeratin 20 (CK20) are
intermediate-sized cytoplasmic structural proteins that form a
major component of the cytoskeleton of human cells (17).
CK7, a marker of ductal differentiation, is not expressed in the
normal epithelium of the gastrointestinal tract or esophagus,
while CK20, a marker of intestinal differentiation, is normally
expressed in the colon and small intestine but is limited to the
surface foveolar epithelium in the stomach (5). Ormbsy et al
(18) described a distinctive CK7/CK20 immunostaining pat-
tern in patients with BE that is highly sensitive and specific.
The immunostaining pattern has a strong, diffuse CK7 staining
of the surface and glandular epithelium, and weak CK20 stain-
ing of the superficial epithelium (18). While these results were
confirmed by later reports (1,19), they were not reproducible
by others (3,20). 
The purpose of the present study was to evaluate the sensi-
tivity and specificity of a semiquantitative CK7/CK20 immunos-
taining pattern for the diagnosis of BE. In addition, we attempt
to explore the pathogenesis of CIM and its relationship with BE
by comparing the two conditions in terms of CK7/CK20
immunostaining pattern, type of IM, associated H pylori infec-
tion, acid reflux, and history of anemia and malignancy, and by
following up on some CIM cases.
METHODS
Patient selection and endoscopy
Biopsies of the SCJ from patients who underwent upper gas-
trointestinal endoscopy and biopsy at Eastern Health
(St John’s, Newfoundland) were retrospectively examined.
Successive biopsies were selected for pathology evaluation,
immunohistochemistry (IHC) staining and analysis if the
specimen was optimal, with full clinical and endoscopic data,
as described below. Endoscopically, the GEJ was identified by
the junction of the tubular esophagus with the most proxi-
mal gastric folds. Histologically, biopsies were obtained from
the SCJ (minimum of three biopsies per patient). To ensure
that biopsies were representative of the SCJ, specimens that
did not contain both squamous and glandular epithelium
were excluded. Suboptimal biopsies (eg, tiny fragmented tis-
sue, lack of superficial or deep epithelial components) were
also excluded. Normal controls included SCJ biopsies with-
out IM, biopsies from the gastric antrum with IM and normal
gastric mucosa. Histological slides were reviewed by
two pathologists. 
Patients’ clinical information (including history of acid
reflux) determined by documented history and/or investiga-
tions, was obtained from clinical charts. H pylori infection was
assessed histologically. Specimens were identified as having
complete or incomplete metaplasia based on periodic acid-
Schiff (PAS) and alcian blue (AB) staining (see below). All
protocols were approved by the Human Investigation
Committee at Memorial University (St John’s, Newfoundland). 
Histology and definitions
Slides were stained with hemotoxylin and eosin using stan-
dard techniques. For case definitions, the criteria of the
American College of Gastroenterology and its Practice
Parameters Committee (21) were used, which have also been
used by recent studies (6,22). The CIM group was defined as
patients with no endoscopic evidence of BE, and a biopsy of
the SCJ that showed IM with goblet cells. Presence of the gas-
tric cardia was confirmed histologically by the presence of
branching mucous glands without parietal cells. Cases of BE
were defined as the presence of tongues of gastric mucosa of
any length (or irregularities of the Z-line) in the lower esoph-
agus and the presence of IM with goblet cells in the histology
biopsy of the SCJ. Normal controls were defined as biopsies
from the SCJ with negative endoscopy and no evidence of IM
on histology. IM of the gastric antrum was defined as the pres-
ence of IM with goblet cells in a histologically confirmed
biopsy from the antrum. 
Immunohistochemical staining for CK7 and CK20
Paraffin blocks were sectioned at a thickness of 4 μm, mounted
on slides and dried overnight. Sections were deparaffinized in
xylene and rehydrated through decreasing graded alcohols.
Slides were immunostained using the Ventana Benchmark
instrument (Ventana Medical Systems Inc, USA) with mono-
clonal antibodies for CK7 (clone OV-TL 12/30, Dako Canada,
Canada; dilution 1:400) and CK20 (clone Ks20.8, Cell
Marque, USA; prediluted by the manufacturer). Antigen
retrieval for the CK7 antibody utilized digestion with
protease 1 for 4 min, while a heat-induced epitope retrieval
using cell conditioner 1 (tris/EDTA/borate buffer, pH 8.0) was
performed for the CK20 antibody. Immune complex was visu-
alized by incubating with diaminobenzidine, and sections were
counterstained with hemotoxylin. 
All slides were reviewed and scored independently by
two pathologists. Disagreements were settled by revised assess-
ment by both pathologists. A semiquantitative assessment was
used to define the BE CK7/CK20 immunostaining pattern.
Immunoreactivity was assessed as both percentage positivity of
slide surface area (negative, 0% to 5%; focal, 6% to 25%;
intermediate, 26% to 50%); and diffuse, 50% to 100%) and
intensity of staining (weak, moderate or strong). Cases were
considered positive for the BE CK7/CK20 immunostaining
pattern if strong, diffuse CK20 staining was observed in the
surface epithelium and superficial glands, and strong, diffuse
CK7 staining was seen in both the superficial and deep glands
(23) (Figure 1). 
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PAS/AB staining 
Slides were hydrated, stained with AB at a pH of 2.5 for 5 min
and washed well with water. Slides were then incubated in 1%
periodic acid stain for 5 min, washed in distilled water, incu-
bated in Schiff reagent for 8 min and washed in running tap
water for 10 min. Slides were then dehydrated, cleared and
mounted. 
Complete IM was defined as mucosal epithelium of the
small intestinal type with mucin-secreting goblet cells, which
stain blue by PAS/AB staining, and nonsecretory absorptive
cells with brush border, which do not stain (Figure 2A) (6).
Incomplete IM has mucin-secreting goblet cells that stain blue
by PAS/AB staining, and secretory columnar mucus cells that
stain red or purple (Figure 2B) (6). 
Statistical analysis 
The statistical significance between groups was assessed by
χ2 analysis and, where appropriate, Fisher’s exact test. For
each variable, the following comparisons were made: BE with
controls, BE with CIM and CIM with controls. Differences
between groups were considered significant when P<0.05.
Sensitivity, specificity, and positive and negative predictive
values were computed from a standard 2×2 table (24). SPSS
13.0 for Windows (SPSS Inc, USA) was used for all statisti-
cal analyses. 
RESULTS
Of 144 consecutive patients who underwent upper gastroin-
testinal endoscopy and biopsy, 19 cases were excluded
because they contained only squamous or glandular epithe-
lium and could not be verified as a true representation of the
SCJ. Another 22 cases were excluded because they were sub-
optimal for evaluation (ie, very fragmented biopsies). The
final sample group comprised 103 cases: 39 with BE, 35 with
CIM and 29 normal SCJ controls. Additionally, 25 biopsies
from the gastric antrum with IM, 15 normal gastric mucosa
(away from the SCJ) and 32 biopsies of normal esophagi,
were included as controls. 
CK7/CK20 immunostaining in Barrett’s esophagus 
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Figure 1) Immunohistochemical staining for cytokeratin 7 (CK7) and cytokeratin 20 (CK20). The Barrett’s esophagus pattern is characterized by
strong, diffuse CK7 staining in both the superficial and deep glands (A) and strong, diffuse CK20 staining in the surface epithelium and superficial
glands (B). A negative Barrett’s esophagus pattern shows no immunoreactivity for CK7 (C) and no or focal weak reactivity for CK20 (D)
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Table 1 shows the distribution of characteristics among the
control, CIM and BE groups. Patient ages ranged from 20 to
89 years, with a mean age of 57 years. Table 2 shows the
CK7/CK20 immunostaining pattern among different groups.
All BE cases (100%) displayed the characteristic BE
CK7/CK20 immunostaining pattern. Only 66% of the CIM
White et al
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TABLE 1
Distribution of characteristics among different patient groups
Group, n (%)
Characteristic Control CIM BE P* P† P‡
Age
<65 y 20 (69.0) 24 (68.6) 25 (64.1) 0.973 0.675 0.685
≥65 y 9 (31.0) 11 (31.4) 14 (35.9)
Sex
Male 11 (37.9) 20 (57.1) 28 (71.8) 0.126 0.005 0.187
Female 18 (62.1) 15 (42.9) 11 (28.2)
Acid reflux
Positive 11 (47.8) 12 (44.4) 28 (71.8) 0.811 0.059 0.025
Negative 12 (52.2) 15 (55.6) 11 (28.2)
Helicobacter pylori infection
Positive 3 (10.3) 6 (17.1) 2 (5.1) 0.436 0.644§ 0.097§
Negative 26 (89.7) 29 (82.9) 37 (94.9)
Intestinal metaplasia
Complete N/A 7 (25.9) 15 (38.5) N/A N/A 0.288
Incomplete 20 (74.1) 24 (61.5)
History of anemia
Positive 4 (13.8) 2 (7.4) 4 (10.3) 0.671§ 0.654 1.00§
Negative 25 (86.2) 25 (92.6) 35 (89.7)
Gastric cancer¶
Positive 2 (6.9) 2 (7.4) 13 (33.3) 1.00§ 0.016§ 0.017§
Gastric lesion**
Positive 3 (10.3) 5 (18.5) 13 (33.3) 0.382 0.027 0.184
Gastrointestinal tumour††
Positive 7 (24.1) 4 (14.8) 8 (20.5) 0.380 0.721 0.555
*Control group versus cardiac intestinal metaplasia (CIM) group; †Control group versus Barrrett’s esophagus (BE) group; ‡CIM group versus BE group; §Fisher’s
exact test; ¶Personal past history of gastric cancer or premalignant condition (adenomatous polyps); **Past or family history of any gastric lesion including cancer,
premalignant condition or benign polyp; ††Past or family history of any gastrointestinal malignant or premalignant condition. N/A Not applicable
Figure 2) Periodic acid-Schiff (PAS) and alcian blue (AB) staining. A Complete intestinal metaplasia, showing mucosal epithelium of the small intes-
tinal type with mucin-secreting goblet cells (stained blue) and nonsecretory absorptive cells with brush border (do not stain). B Incomplete intestinal
metaplasia, showing mucin-secreting goblet cells (stained blue) and secretory columnar mucous cells (stained red or purple)
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biopsies displayed this pattern. When the subgroup of CIM
patients with a history of acid reflux was evaluated for the BE
staining pattern, 100% of cases were positive. None of the
biopsies with IM of the antrum, normal stomach or esophagus,
showed the BE CK7/CK20 immunostaining pattern.
The sensitivity and specificity of the CK7/CK20 immuno-
staining pattern for BE and CIM patients is displayed in
Table 3. Sensitivity was higher in the BE group than in the
CIM group (100% versus 66%, respectively), while the speci-
ficity was 80% for both groups. The positive and negative pre-
dictive values (83% and 100%, respectively) in the BE group
were higher than those in the CIM group (74% and 73%,
respectively). In the subgroup of CIM patients with acid reflux,
the sensitivity increased to 100% (Table 3). 
An interesting subgroup of eight patients was analyzed fur-
ther. In this subgroup, endoscopic results were positive
(ie, presence of tongues of gastric mucosa extending to a vari-
able length into the proximal esophagus), and showed the
CK7/CK20 BE immunostaining pattern on IHC, but they all
lacked evidence of IM by histological assessment. When re-
evaluated using auxiliary testing and clinical data, two of
these cases showed focal IM by PAS/AB staining. Out of the
remaining six cases, three showed IM in a previous biopsy,
and two showed IM in a follow-up biopsy after one to
two years. There was no follow-up available for the remaining
case. These findings suggest that in an endoscopically posi-
tive individual, the CK7/CK20 immunostaining pattern
might be a more sensitive indicator of BE than histological
identification of IM. 
In an attempt to elucidate the pathogenesis of CIM and its
relationship with BE, the two conditions were compared with
each other and with the control group with respect to different
characteristics (Table 1). There was no significant difference
between these groups regarding age, H pylori infection or his-
tory of anemia. There was a statistically significant male pre-
dominance in the BE group when compared with controls
(P=0.005). There was a statistically significant difference in
the presence of acid reflux (documented by the presence of
symptoms, patient recall and/or clinical investigations)
between the BE and the CIM groups (P=0.025). A similar trend
was seen when the BE and control groups were compared, but
this value did not reach statistical significance. There was a sta-
tistically significant predominance of a history of gastric cancer
or premalignant condition in the BE group compared with the
CIM group (P=0.017) and the control group (P=0.016). Also,
the BE group had more patients with a past or family history of
gastric lesions than the control group (P=0.027).
The subgroup of CIM patients with a history of acid reflux
showed 100% positivity for the CK7/CK20 staining pattern
(Table 2). On the other hand, in the subgroup of CIM with
positive CK7/CK20 immunostaining pattern, the frequency of
acid reflux was higher than the total CIM population (100%
versus 34%) (data not shown).
Of 26 cases of CIM where follow-up endoscopy was avail-
able, four cases (15%) progressed to BE within two years, and
one patient developed dysplasia. All four cases showed a posi-
tive BE pattern of CK7/CK20 immunostaining and all were
negative for H pylori infection. Three of these patients were
male and one was female. Two patients had incomplete and
two had complete IM (data not shown).
DISCUSSION
Our results of a semiquantitative assessment show that the BE
pattern of immunostaining is 100% sensitive and 80% specific
in patients with BE, but this pattern appears to be less sensitive
(66%) for CIM. These results are similar to some previous
reports (5,25), but were not always reproducible. The apparent
discrepancy between studies may be due to a number of factors,
including inaccurate visualization of short segment BE on
endoscopy, interobserver variability, tissue fixation differences,
and immunohistochemical staining differences (eg, antigen
retrieval methods (25). Another important factor is the
anatomical location from which the biopsy was taken, because
biopsies obtained distal to the cardia have a significantly lower
likelihood of showing a BE pattern. 
To our knowledge, the present report is the first to provide
evidence that the BE immunostaining pattern is more sensi-
tive than histology in detecting BE. Follow-up of histologi-
cally negative specimens that were positive by endoscopy and
immunostaining showed that IM was documented in these
patients in a follow-up biopsy or by auxiliary testing. Our find-
ings suggest that a semiquantitative CK7/CK20 immunostain-
ing pattern can be used to confirm BE, even when goblet cells
are not identifiable histologically. A larger scale study should
be performed to confirm these findings.
The prevalence of CIM in the general population and its
clinical significance has not yet been confirmed. Polkowski
et al (6), found IM in 12% of their normal study population.
Their study sample, however, should not be considered a
CK7/CK20 immunostaining in Barrett’s esophagus 
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TABLE 2
Barrett’s esophagus (BE) cytokeratin 7 and cytokeratin 20
immunostaining pattern among different patient groups
BE pattern*, n (%) 
Group Positive Negative Total
BE† 39 (100) 0 39
Cardiac intestinal metaplasia† 23 (66) 12 (34) 35
Cardiac intestinal metaplasia with 12 (100) 0 12
acid reflux‡
Gastric antral metaplasia† 0 25 (100) 25
Normal stomach† 0 15 (100) 15
Normal esophagus† 0 32 (100) 32
*Positive cases are defined as having the characteristic BE immunostaining
pattern as described in the methods section; †For category definitions, see
the methods section; ‡Defined as the presence of intestinal metaplasia with
goblet cells in endoscopy-negative individuals with a history of acid reflux
TABLE 3
Sensitivity, specificity, and positive and negative
predictive values of the Barrett’s esophagus (BE)
cytokeratin 7 and cytokeratin 20 immunostaining pattern
in cases of BE and cardiac intestinal metaplasia (CIM)
Variable BE* CIM* CIM + acid†
Sensitivity‡, % 100 66 100
Specificity‡, % 80 80 73
Positive predictive value‡, % 83 74 73
Negative predictive value‡, % 100 73 100
*For case definitions, please see the methods section; †The subgroup of CIM
patients with a history of acid reflux; ‡Values are computed from a standard
2×2 table (24)
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representation of a ‘normal’ population because it consisted
mainly of patients who underwent gastroesophagectomy resec-
tion for cancer, which is a population in which we expect to
see more of the metaplasia-dysplasia axis in the surrounding
tissues. Others suggest that CIM represents a response to stress-
ful stimuli. The nature of these stimuli could be acid reflux or
other etiologies such as H pylori infection (12,13). 
The relationship between BE and IM of the gastric cardia
is still a matter of dispute (5). Reports have tried to differenti-
ate the two conditions based on the staining patterns, but
results are inconsistent. Another differentiating factor that
has been tested is the type of IM, which can be either incom-
plete or complete. DeMeester et al (5), suggested that in
patients with reflux as the etiology for their CIM, IM tends to
be incomplete (similar to that of BE). In contrast, CIM sec-
ondary to H pylori infection tends to produce complete IM.
Incomplete IM was found to be associated with an increased
risk for cancer (26) and is considered a premalignant lesion in
the distal stomach (27,28). Similarly, incomplete IM was
found to be associated with adenocarcinoma of the esophagus,
arising within a background of BE (29). Our findings did not
show a significant difference in the type of IM (complete ver-
sus incomplete) between CIM and BE (P=0.288), although
there is a comparable trend toward incomplete IM in both
conditions (Table 1). This is contradictory to a previous
report (6), likely due to differences in sample size or the pop-
ulation selection bias. 
Based on our findings, we hypothesize that CIM represents
a response to stressful stimuli that might be either acid reflux
or H pylori infection. Our results provide several lines of evi-
dence that BE and the subgroup of CIM with a history of acid
reflux are two conditions within the same spectrum. This sub-
set can possibly be identified by the CK7/CK20 immunostain-
ing pattern, and is a precursor of BE. Similar to previous
reports (5,19), both conditions show considerable overlap of a
specific CK7/CK20 immunostaining pattern that is not seen in
other normal anatomical regions or IM of other parts of the
stomach (Table 2). In the subgroup of CIM patients with acid
reflux, the sensitivity of the BE pattern of IHC increased to
100% (compared with 66% in the total CIM population). In
addition, there are no statistically significant differences
between the two conditions regarding other parameters, such
as the type of IM, associated H pylori infection, acid reflux his-
tory, history of anemia and malignancy. Moreover, of 26 cases
of CIM where follow-up endoscopy was available, four cases
(15%) progressed to BE within two years. All four cases
showed a positive BE pattern of CK7/CK20 immunostaining,
and all were negative for H pylori infection. Three of these
patients were male and one was female. Interestingly, there is a
documented male predominance of adenocarcinoma of the
esophagus (30). 
Our findings that CIM is not necessarily linked to H pylori
infection (Table 1) is supported by recent epidemiological evi-
dence. H pylori is a known risk factor for the development of gas-
tritis and IM. Worldwide, the incidence of gastric cancer is
declining, most likely due to the decrease of infection by H pylori
(31,32). An opposite trend is seen in the cardia, with increasing
incidence of cardiac adenocarcinoma, despite decreasing
H pylori infection. 
Our hypothesis, if proven by larger scale studies, could
resolve the apparent contradiction in previous studies. El-Serag
et al (33) and Goldblum et al (34) suggest that gastroe-
sophageal reflux disease is not a risk factor for CIM. On the
other hand, Oberg et al (35) reported the development of car-
diac mucosa (with some proceeding to IM) in the proximal
esophagus after esophagectomy, suggesting that this is an
acquired condition related to acid exposure. Interestingly,
Sharma et al (16) found that there was a higher prevalence
and incidence of dysplasia in their short segment BE group
than in their CIM group (11.3% versus 4.6%, respectively).
These data support our hypothesis that the development of BE
is a progression from CIM to BE, then to dysplasia. Further
studies should be performed to determine whether the pres-
ence or absence of a BE pattern of CK7/CK20 immunostaining
could predict progression to dysplasia or carcinoma, as previ-
ously suggested (25). 
CONCLUSIONS
Our findings suggest that the CK7/CK20 immunostaining pat-
tern is sensitive and specific for BE, and that a semiquantita-
tive CK7/CK20 immunostaining pattern can be used to
confirm BE, even when goblet cells are not histologically iden-
tified. In addition, we hypothesize that CIM represents a
response to stressful stimuli such as acid reflux and H pylori
infection. The semiquantitative CK7/CK20 immunostaining
pattern can help to subgroup CIM into acid-related and non-
acid-related groups. The former subgroup might represent an
earlier ‘phase’ of BE that requires less rigorous follow-up than
BE patients, but yet more than CIM patients who currently
have no follow-up. 
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